EUVIMEDEUVIMED entdecken
Crossref

Polyphenols in Type 2 Diabetes Mellitus: Mechanistic Evidence, Emerging Targets, and Translational Potential: A Narrative Review

HY Mailabari, AO Omoaghe, KS Olaniyi

Journal of Medicine and Biomedical Research · 2026 · 25 (1) · 90-101

DOI: 10.4314/jmbr.v25i1.12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicine and Biomedical Research, 2026. Verfasst von HY Mailabari und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 diabetes mellitus (T2DM) affects over 590 million adults worldwide and remains a leading cause of cardiovascular, renal, and hepatic complications. Despite advances in pharmacotherapy, current agents primarily target glycaemic control while leaving oxidative stress and chronic inflammation inadequately addressed. This review aimed to comprehensively elucidate how polyphenols modulate oxidative stress, inflammation, insulin resistance, β-cell function, and metabolic regulation in T2DM, while critically evaluating translational potential, clinical evidence, and future integrative strategies.

Discussion

Polyphenols, a diverse class of >8,000 plant-derived metabolites, have emerged as adjunctive candidates for T2DM. Preclinical studies consistently demonstrate their ability to modulate oxidative stress, inflammatory signalling, insulin sensitivity, β-cell survival, lipid metabolism, and gut microbiota. Human trials, though fewer in number, report modest improvements in fasting glucose, glycated haemoglobin (HbA1c), and lipid parameters. This review provides an integrated mechanistic synthesis of polyphenol actions, highlighting caffeic acid, quercetin, and resveratrol as exemplary compounds. Unlike prior reviews, this article bridges the molecular mechanisms-translational gap, situating polyphenols within the bench-to-bedside continuum. We critically assess challenges including poor bioavailability, heterogeneous trial outcomes, and lack of supplement standardisation, and we discuss solutions such as nanoformulations, polyphenol-drug synergies, and precision nutrition strategies.

Conclusion

By integrating mechanistic, translational, and microbiota evidence into a unified framework, this review positions polyphenols as holistic adjuncts in the management of T2DM. Future directions include large-scale, biomarker-driven clinical trials and systems biology approaches to fully harness their therapeutic potential.

Zitieren

APA

Mailabari, H., Omoaghe, A., & Olaniyi, K. (2026). Polyphenols in Type 2 Diabetes Mellitus: Mechanistic Evidence, Emerging Targets, and Translational Potential: A Narrative Review. Journal of Medicine and Biomedical Research, 25(1), 90-101. https://doi.org/10.4314/jmbr.v25i1.12

Vancouver

Mailabari H, Omoaghe A, Olaniyi K. Polyphenols in Type 2 Diabetes Mellitus: Mechanistic Evidence, Emerging Targets, and Translational Potential: A Narrative Review. Journal of Medicine and Biomedical Research. 2026;25(1):90-101. doi:10.4314/jmbr.v25i1.12

BibTeX
@article{Mailabari2026,
  author = {Mailabari, HY and Omoaghe, AO and Olaniyi, KS},
  title = {Polyphenols in Type 2 Diabetes Mellitus: Mechanistic Evidence, Emerging Targets, and Translational Potential: A Narrative Review},
  journal = {Journal of Medicine and Biomedical Research},
  year = {2026},
  volume = {25},
  number = {1},
  pages = {90--101},
  doi = {10.4314/jmbr.v25i1.12}
}
Kostenlos starten →